#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14038	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2129	655.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1696	1696	T	771	T	707	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14038	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2129	655.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1430	1430	C	820	C,A	759,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25088	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3520	710.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1635	1635	A	866	A,G	806,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25088	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3520	710.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2269	2269	C	781	C,T,G	730,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25088	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3520	710.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2343	2343	A	809	A	756	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25088	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3520	710.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2895	2895	C	791	C,A	749,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	27	2034	folP	852	852	100.0	folP.l15.c30.ctg.1	1590	127.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1047	1049	AGC	212;214;216	A;G;C	186;191;187	folP.WHO_W_01420c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5394	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3338	161.0	1	SNP	p	S91F	0	.	.	271	273	TCC	558	560	TCC	207;205;206	T;C,A;C	191;189,1;190	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5394	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3338	161.0	1	SNP	p	D95G	0	.	.	283	285	GAC	570	572	GAC	202;201;200	G,T;A;C	185,1;182;182	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5394	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3338	161.0	1	SNP	p	D95N	0	.	.	283	285	GAC	570	572	GAC	202;201;200	G,T;A;C	185,1;182;182	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1342	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1266	105.4	0	.	p	.	0	A39T	NONSYN	115	117	GCC	394	396	ACC	151;151;148	A;C,T;C	137;141,1;141	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1342	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1266	105.4	0	.	p	.	0	R44H	NONSYN	130	132	CGC	409	411	CAC	148;149;150	C,A;A;C	139,1;141;142	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1342	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1266	105.4	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	592	594	CAC	211;208;210	C;A;C	192;188;192	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1342	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1266	105.4	1	SNP	p	G45D	0	.	.	133	135	GGC	412	414	GGC	149;147;147	G;G;C	139;138;140	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	706	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	868	80.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5758	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2903	197.7	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1637	1639	GCA	252;254;252	G;C;A,G	237;229;228,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5758	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2903	197.7	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2120	2122	ATT	249;251;248	A;T;T	225;226;225	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5758	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2903	197.7	1	SNP	p	D86N	0	.	.	256	258	GAC	590	592	GAC	212;213;212	G;A;C	205;202;202	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5758	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2903	197.7	1	SNP	p	S87I	0	.	.	259	261	AGT	593	595	AGT	211;211;211	A;G;T	203;205;199	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5758	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2903	197.7	1	SNP	p	S87R	0	.	.	259	261	AGT	593	595	AGT	211;211;211	A;G;T	203;205;199	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5758	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2903	197.7	1	SNP	p	S87W	0	.	.	259	261	AGT	593	595	AGT	211;211;211	A;G;T	203;205;199	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5758	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2903	197.7	1	SNP	p	S88P	0	.	.	262	264	TCC	596	598	TCC	210;215;214	T;C;C	202;206;207	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4088	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2597	156.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1600	1602	GGC	201;199;200	G;G;C	184;183;179	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.15.001	penA.15.001	1	1	27	3686	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2454	149.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1249	1251	GCA	180;181;182	G;C;A	166;169;171	penA.15.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3686	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2454	149.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1252	1254	ATC	183;181;180	A;T;C	170;170;169	penA.15.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3686	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2454	149.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1264	1266	GTG	184;184;185	G;T;G	178;177;176	penA.15.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3686	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2454	149.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1264	1266	GTG	184;184;185	G;T;G	178;177;176	penA.15.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3686	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2454	149.8	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1765	1767	ACC	207;204;205	A;C;C	183;187;188	penA.15.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3686	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2454	149.8	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1819	1821	GCG	183;180;179	G;C;G	150;141;141	penA.15.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3686	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2454	149.8	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1819	1821	GCG	183;180;179	G;C;G	150;141;141	penA.15.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3686	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2454	149.8	1	SNP	p	G542S	0	.	.	1624	1626	GGC	1942	1944	GGC	165;164;164	G;G;C	150;151;150	penA.15.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3686	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2454	149.8	1	SNP	p	G545S	0	.	.	1633	1635	GGC	1951	1953	GGC	161;160;161	G;G;C	143;143;144	penA.15.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3686	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2454	149.8	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1969	1971	CCG	143;149;151	C,G;C,G;G	105,2;112,1;115	penA.15.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5392	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3274	164.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2216	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1681	130.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	528	528	C	145	C	132	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	470	472	GGA	183;181;183	G;G;A	176;174;173	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	F135L	NONSYN	403	405	TTT	731	733	CTT	215;216;214	C;T;T	198;198;198	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	R143G	NONSYN	427	429	AGA	755	757	GGA	234;233;233	G,A;G,A;A	218,1;217,1;217	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	G189S	NONSYN	565	567	GGC	893	895	AGC	258;257;257	A;G;C	240;241;239	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	Y211_N212insDGQ	INS	631	631	T	959	959	T	260	T	239	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	N212_S213insL	INS	634	634	A	972	972	C	247	C,T,A	225,1,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	I214M	NONSYN	640	642	ATC	980	982	ATG	248;242;243	A,G;T;G,C	227,1;225;221,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	L218F	NONSYN	652	654	CTT	992	994	TTT	250;249;251	T;T,C;T	229;229,1;230	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	A238V	NONSYN	712	714	GCC	1052	1054	GTT	230;230;228	G;T;T	220;219;218	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	T252A	NONSYN	754	756	ACA	1094	1096	GCA	213;209;211	G;C;A	203;198;202	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	W253T	NONSYN	757	759	TGG	1097	1099	ACG	212;211;215	A;C;G	203;202;204	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	S254R	NONSYN	760	762	AGT	1100	1102	AGG	214;214;215	A;G;G	202;203;204	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	A255V	NONSYN	763	765	GCT	1103	1105	GTT	217;217;214	G;T;T	206;201;203	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	L275V	NONSYN	823	825	TTA	1163	1165	GTA	230;229;228	G;T;A	209;207;205	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	S288T	NONSYN	862	864	TCT	1202	1204	ACT	228;228;229	A;C,G;T	211;210,1;213	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	H290D	NONSYN	868	870	CAT	1208	1210	GAT	225;224;222	G;A;T	213;213;209	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	S291D	NONSYN	871	873	AGT	1211	1213	GAT	223;225;224	G;A;T	208;211;213	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	D293N	NONSYN	877	879	GAC	1217	1219	AAC	234;232;232	A;A;C	221;216;220	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	Y294H	NONSYN	880	882	TAC	1220	1222	CAC	232;231;232	C;A;C	220;220;219	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	0	.	p	.	0	E329D	NONSYN	985	987	GAA	1325	1327	GAC	256;253;255	G;A;C	240;240;242	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	1	SNP	p	G120K	0	.	.	358	360	GGT	686	688	GGT	191;192;193	G;G;T	174;174;170	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	1	SNP	p	A121D	0	.	.	361	363	GCC	689	691	GCC	190;188;187	G;C;C	168;169;168	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2724	porB1b	1035	1035	96.47	porB1b.l15.c4.ctg.1	1585	171.1	1	SNP	p	A121N	0	.	.	361	363	GCC	689	691	GCC	190;188;187	G;C;C	168;169;168	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10116	rpoB	4179	4179	99.98	rpoB.l6.c30.ctg.1	4691	214.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1909	1911	CAT	208;209;208	C,A;A;T	189,1;191;191	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1126	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1068	104.6	1	SNP	p	V57M	0	.	.	169	171	GTG	638	640	GTG	230;228;233	G;T;G	217;214;219	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
